

DX01170K1 US

**Application 10/749,144**  
**Draft Claims for Discussion Only**  
**October 29, 2007**

**RECEIVED**  
**CENTRAL FAX CENTER**

OCT 29 2007

33 (New): A method of inhibiting IL-17C activity in a subject with psoriasis, comprising administering to the subject a binding composition, wherein the binding composition comprises an antigen binding site of an antibody that specifically binds to a human IL-17C protein and blocks binding of the IL-17C protein to the extracellular domain of a human IL-17RE protein, wherein the human IL-17C protein comprises the mature sequence in SEQ ID NO:24 and the extracellular domain of the human IL-17RE protein comprises amino acids 1-424 of SEQ ID NO:12.

34 (New): The method of Claim 21, wherein the antibody is:

- a) a polyclonal antibody;
- b) a monoclonal antibody; or
- c) a humanized antibody

35 (New): The method of Claim 23, wherein the antibody is a humanized antibody.